Hong Kong Construction Stock News

China East Education Holdings' (HKG:667) stock is up by a considerable 13% over the past week. However, we wonder if...

Shanghai MicroPort MedBot (Group) (SEHK:2252) is back on investors’ radar after reporting more than 200 commercial orders for its Toumai laparoscopic surgical robot, with around 130 systems installed across nearly 50 countries and regions. See our latest analysis for Shanghai MicroPort MedBot (Group). The recent Toumai order momentum and remote surgery progress come as the shares trade at HK$29.0, with an 11.71% 1 day share price return and 22.99% 90 day share price return, alongside a 50.57%...

GCL Technology Holdings Limited ( HKG:3800 ) shareholders should be happy to see the share price up 11% in the last...

Over the last month the Pacific Century Premium Developments Limited ( HKG:432 ) has been much stronger than before...

As you might know, NetEase, Inc. ( HKG:9999 ) recently reported its annual numbers. It looks like the results were a...

Pacific Century Premium Developments Limited ( HKG:432 ) shareholders have had their patience rewarded with a 45% share...

Key Insights China Wantian Holdings' significant private companies ownership suggests that the key decisions are...

Congyu Intelligent Agricultural Holdings Limited ( HKG:875 ) shareholders that were waiting for something to happen...

Despite an already strong run, China High Speed Transmission Equipment Group Co., Ltd. ( HKG:658 ) shares have been...

Vobile Group (SEHK:3738) has drawn fresh attention after announcing a collaboration with Finloop Finance Technology to tokenize offshore real world assets tied to cultural and creative intellectual property, with the aim of building a compliant IP backed digital asset ecosystem. See our latest analysis for Vobile Group. The Finloop agreement lands at a time when momentum in Vobile Group’s shares has been picking up, with a 7 day share price return of 37.09% and a year to date share price...

Lenovo Group (SEHK:992) has just posted its Q3 2026 numbers, with revenue of about US$22.2 billion and basic EPS of US$0.044, backed by net income of US$545.5 million. The company has seen quarterly revenue move from US$16.98 billion in Q4 2025 to US$18.83 billion in Q1 2026, US$20.45 billion in Q2 2026, and now US$22.20 billion in Q3 2026. Over the same stretch, EPS has ranged between US$0.007 and US$0.056 and sits at US$0.044 this quarter, highlighting a story that is as much about the...

Budweiser Brewing Company APAC (SEHK:1876) closed out FY 2025 with Q4 revenue of US$1,073 million and a basic EPS loss of US$0.01, while trailing twelve month EPS was US$0.04 on revenue of US$5.8 billion. Over recent quarters the company reported revenue of US$1,461 million in Q1 2025, US$1,675 million in Q2, US$1,555 million in Q3 and US$1,073 million in Q4, with quarterly EPS ranging from US$0.02 in Q1 to a small loss in Q4. This presents a mixed picture on profitability as margins came...

NetEase Cloud Music (SEHK:9899) just posted its FY 2025 numbers, with second half revenue at C$3,932 million and basic EPS of C$4.08, capping a trailing twelve month EPS of C$13.02 on C$7.8 billion of revenue and C$2,748 million of net income from core operations. Over the past few reporting periods the business has seen revenue move from C$3,880 million in 2H 2024 to C$3,827 million in 1H 2025 and C$3,932 million in 2H 2025, while basic EPS shifted from C$3.60 to C$8.96 and then to C$4.08...

As global markets experience volatility with mixed results across major indices, the focus has shifted towards small-cap and value-oriented stocks, which have shown resilience amidst concerns over artificial intelligence investments and geopolitical tensions. In this dynamic environment, identifying promising high-growth tech stocks in Asia requires a keen understanding of market trends and economic indicators that can influence their potential for growth.

As global markets navigate a mixed landscape marked by volatility and shifts in investor sentiment, Asia's stock markets continue to capture attention with their unique opportunities. Penny stocks, though often viewed as speculative, can offer intriguing possibilities for growth, particularly when they are supported by strong financial health and solid fundamentals. In this article, we explore three Asian penny stocks that stand out for their potential to deliver impressive returns while...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

China Telecom Corporation Limited ( HKG:728 ) shareholders might be concerned after seeing the share price drop 15% in...

Pacific Basin Shipping Limited ( HKG:2343 ), is not the largest company out there, but it received a lot of attention...

China Ruifeng Renewable Energy Holdings Limited ( HKG:527 ) shares have had a really impressive month, gaining 38...

When close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") above 13x, you may consider...

Celestial Asia Securities Holdings Limited ( HKG:1049 ) shares have continued their recent momentum with a 33% gain in...

International Business Digital Technology Limited ( HKG:1782 ) shareholders have had their patience rewarded with a 25...

As global markets navigate a mix of economic signals, with small-cap and value-oriented stocks gaining traction amidst concerns over artificial intelligence investments, Asia's market landscape presents unique opportunities for investors seeking potential growth. In this dynamic environment, identifying promising stocks often involves looking for companies that can capitalize on regional trends and demonstrate resilience in the face of broader market volatility.

Ascentage Pharma Group International (SEHK:6855) received investigational new drug clearance in China for APG-3288, its next generation BTK targeted protein degrader. The Chinese clearance follows earlier U.S. FDA approval for clinical testing, aligning the program across two major drug development markets. APG-3288 is being developed for treatment resistant blood cancers, with a focus on hematologic malignancies that do not respond to existing BTK therapies. For investors tracking oncology...